general practice. In a recent survey of general practices in the Thames Valley area and Lambeth (where 67.9% of practices had Asian or African Caribbean populations constituting >8% of the total population), none were supplementing pregnant women with vitamin D (11).

On the basis of the abovementioned evidence, we believe that, at a minimum, the DOH recommendations should be followed, and all pregnant and breastfeeding women should receive 10 μg (400 IU) vitamin D/d. We also echo the concerns raised by others concerning the recommendations of NICE (12, 13) and call for clarity.

The authors had no conflict of interest to declare.

Puneet Arora
Obstetrics and Gynaecology
Queen’s Park Hospital
Blackburn
United Kingdom

Ramandeep S Arora
Paediatrics
Royal Manchester Children’s Hospital
Manchester
United Kingdom
E-mail: reemaraman@doctors.org.uk

REFERENCES

Insulin secretion and capsaicin
Dear Sir:

Many studies in the medical literature have indicated that the consumption of chili-containing meals increases energy expenditure and fat oxidation. Moving toward this direction, a new study regarding the metabolic effect of a capsaicin chili–containing meal after the consumption of a bland diet and a chili-blend–supplemented diet was performed by Ahuja et al (1). The authors concluded that regular consumption of chili may attenuate postprandial hyperinsulinemia. To our knowledge, many studies have reported different effects of capsaicin on glucose metabolism, implying that several factors may be responsible for or may interact with capsaicin at a molecular level, receptor level, or both. In one of the first studies of the effects of capsaicin on glucose metabolism, Karlsson et al (2) showed in mice that both the early (1-min) insulin secretory response to intravenous glucose and glucose elimination were potentiated after capsaicin administration, whereas basal insulin concentrations were not affected by capsaicin. Similarly, in their experimental studies in rats, Gram et al (3) reported that the mean blood glucose concentration decreased and the plasma insulin concentration was unchanged during an oral-glucose-tolerance test (OGTT) after capsaicin administration, whereas the administration of a tolerable analogue of capsaicin suitable for in vivo use (resiniferatoxin) was accompanied by an increased insulin response to oral glucose (4). In addition, Akiha et al (5) showed in another study in rats that systemic administration of 10 mg capsaicin/kg (subcutaneously) dose-dependently increased insulin secretion and plasma insulin concentrations 1 h after treatment. Other experimental studies conducted by Tolan et al (6, 7) showed that purified capsaicin caused a decrease in blood glucose concentrations in dogs during an OGTT and a concomitant elevation in plasma insulin concentrations. Another study of insulin metabolism after oral application of capsaicin by Domotor et al (8) conducted in healthy human subjects showed that, although the plasma concentrations of insulin increased from 90 to 165 min after glucose loading, there were no significant differences between the results obtained with and without capsaicin administration. Although many studies of the role of capsaicin in carbohydrate metabolism have been performed on animals, most of which showed that (contrary to the results of Ahuja et al) capsaicin is associated with increased insulin secretion, most of these studies were conducted under different experimental circumstances and, although adding some evidence for a better understanding of the role of capsaicin in carbohydrate metabolism, their results are hardly comparable. However, to date, there is a paucity of human studies on the effects of capsaicin on glucose metabolism. In conclusion, it seems that several influencing and confounding factors, as well as differences in animal and human metabolisms, could at least partly explain why the results of the study by Ahuja et al contrasted with those of other studies. Although the time of a clinical application of capsaicin analogues in treating metabolic disorders such as diabetes is still distant, and even though there is a lack of more solid evidence, we believe that largescale clinical trials are needed.

None of the authors had a personal or financial conflict of interest.

Alevizos Alevizos
Constantinos Mihas
Anargiros Mariolis
Department of General Practice and Family Medicine
Health Centre of Vyronas
3 Korytsas Street
16231 Athens
Greece

Department of Dermatology
“A Sygros” General Hospital
Athens
Greece
E-mail: alevisos@gmail.com

REFERENCES

Erratum

On page 975 (right column), the last sentence of paragraph 3 should read as follows: The incorporation of lupin kernel fiber into processed foods was found to result in higher postmeal satiety up to 4.5 h and lower energy intake (≈15%) over the test day (20). In this article, “LKF” represents “lupin kernel flour” (of which fiber is a major component), not “lupin kernel fiber.”